Intravoxel Incoherent Motion (IVIM) is capable of providing both diffusion and perfusion quantification using a single imaging study at the same time, without the need for intravenous contrast injection. acute myeloid leukemia (AML) patients with complete remission and non-complete remission could exhibit different characterizations before treatment in perfusion and tissue cellularity of the lumbar bone marrow. This study was to investigate the usefulness of IVIM parameters in evaluation of prognosis in AML patients.
[1]EsteyE,DöhnerH .Acute myeloid leukaemia. Lancet 2006 ; 368 ( 9550 ): 1894 – 1907 .
[2] Ferrara F ,Palmieri S , Leoni F . Clinically useful prognostic factors in acute myeloid leukemia .Crit Rev OncolHematol2008 ;66 ( 3 ): 181 – 193 .
[3]BourillonC, Rahmouni A, Lin C, et al.Intravoxelincoherent motion diffusion-weighted Imaging of multiple myeloma lesions: correlation with whole-body dynamic contrast agent-enhanced MR imaging[J].Radiology,2015, 277(3): 773-783.
[4]Koh DM, Collins DJ, Orton MR. Intravoxel incoherent motion in body diffusion-weighted MRI: reality and challenges. American Journal of Roentgenology ,2011,196(6):1351-1361.
[5]. Takahara T, Kwee TC. Low b-value diffusion-weighted imaging: emerging applications in the body. J MagnReson Imaging. 2012,35(6):1266-1273.
Figure1:(a-d) One patient with AML,male,25 Y, achieved CR after the first remission induction chemotherapy, (a) ADCmap, ADC=0.490×10-3mm2/s; (b) D map, D=0.243×10-3mm2 /s; (c) D*map, D*=66.0×10-3mm2 /s; (d) f map, f=0.201. (e-h) Another patient with AML, male,48 Y, achieved NR after the first remission induction chemotherapy:(e) ADCmap, ADC=0.468×10-3mm2 /s; (f) D map, D=0.199×10-3mm2 /s; (g) D*map, D*=64.8×10-3mm2 /s;(h) f map, f=0.281. Color bars of the two patients are the same.